Use of proton pump inhibitors and the risk of listeriosis: A nationwide registry-based case-control study

Anne Kvistholm Jensen, Jacob Simonsen, Steen Ethelberg

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND: Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis. We aimed to investigate a potential association in cases of non-pregnancy associated listeriosis, using registry data.

METHODS: We conducted a population-based case-control study using Danish health registries. Case-patients (n=721) were defined as patients ≥45 years notified with listeriosis, July 1994 to December 2012. We selected 34,800 control-subjects by risk-set sampling. Controls were individually matched for age, sex, municipality and time. Person data on use of PPI and other drugs and hospitalization diagnoses in a 5-year period were extracted from nationwide health registries. A comorbidity index (CMI) was constructed. We calculated the association with use of PPIs and related drugs within 30 days (current use) and other time windows before the index date. Using conditional logistic regression, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.

RESULTS: The adjusted OR with current use of PPIs for development of listeriosis was 2.81 (95% confidence interval [CI], 2.14-3.69). PPI usage up to 90 days before the index date remained statistically significant. Subgroup analyses revealed increasing ORs with decreasing age and level of comorbidity, and an increased OR for concurrent glucocorticoid treatment (OR 4.61; 95% CI, 3.01-7.06). No significant association was found for current use of histamine-2-receptor antagonists, adjusted OR, 1.82 (95% CI, 0.89-3.71).

CONCLUSIONS: Prescribed PPIs were associated with an increased risk of listeriosis. The risk waned with time since last prescription redemption. PPIs may have unwanted side effects in vulnerable populations groups.

OriginalsprogEngelsk
TidsskriftClinical Infectious Diseases
Vol/bind64
Udgave nummer7
Sider (fra-til)845-851
ISSN1058-4838
DOI
StatusUdgivet - 2017

Fingeraftryk

Registries
Case-Control Studies
Odds Ratio
Comorbidity
Confidence Intervals
Histamine Receptors
Health
Vulnerable Populations
Pharmaceutical Preparations
Glucocorticoids
Prescriptions
Logistic Models
Population

Citer dette

Jensen, Anne Kvistholm ; Simonsen, Jacob ; Ethelberg, Steen. / Use of proton pump inhibitors and the risk of listeriosis : A nationwide registry-based case-control study. I: Clinical Infectious Diseases. 2017 ; Bind 64, Nr. 7. s. 845-851.
@article{de8ae9c1f7a34325add51eae3ba0f466,
title = "Use of proton pump inhibitors and the risk of listeriosis: A nationwide registry-based case-control study",
abstract = "BACKGROUND: Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis. We aimed to investigate a potential association in cases of non-pregnancy associated listeriosis, using registry data.METHODS: We conducted a population-based case-control study using Danish health registries. Case-patients (n=721) were defined as patients ≥45 years notified with listeriosis, July 1994 to December 2012. We selected 34,800 control-subjects by risk-set sampling. Controls were individually matched for age, sex, municipality and time. Person data on use of PPI and other drugs and hospitalization diagnoses in a 5-year period were extracted from nationwide health registries. A comorbidity index (CMI) was constructed. We calculated the association with use of PPIs and related drugs within 30 days (current use) and other time windows before the index date. Using conditional logistic regression, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.RESULTS: The adjusted OR with current use of PPIs for development of listeriosis was 2.81 (95{\%} confidence interval [CI], 2.14-3.69). PPI usage up to 90 days before the index date remained statistically significant. Subgroup analyses revealed increasing ORs with decreasing age and level of comorbidity, and an increased OR for concurrent glucocorticoid treatment (OR 4.61; 95{\%} CI, 3.01-7.06). No significant association was found for current use of histamine-2-receptor antagonists, adjusted OR, 1.82 (95{\%} CI, 0.89-3.71).CONCLUSIONS: Prescribed PPIs were associated with an increased risk of listeriosis. The risk waned with time since last prescription redemption. PPIs may have unwanted side effects in vulnerable populations groups.",
keywords = "Journal Article",
author = "Jensen, {Anne Kvistholm} and Jacob Simonsen and Steen Ethelberg",
note = "{\circledC} The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2017",
doi = "10.1093/cid/ciw860",
language = "English",
volume = "64",
pages = "845--851",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Heinemann",
number = "7",

}

Use of proton pump inhibitors and the risk of listeriosis : A nationwide registry-based case-control study. / Jensen, Anne Kvistholm; Simonsen, Jacob; Ethelberg, Steen.

I: Clinical Infectious Diseases, Bind 64, Nr. 7, 2017, s. 845-851.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Use of proton pump inhibitors and the risk of listeriosis

T2 - A nationwide registry-based case-control study

AU - Jensen, Anne Kvistholm

AU - Simonsen, Jacob

AU - Ethelberg, Steen

N1 - © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis. We aimed to investigate a potential association in cases of non-pregnancy associated listeriosis, using registry data.METHODS: We conducted a population-based case-control study using Danish health registries. Case-patients (n=721) were defined as patients ≥45 years notified with listeriosis, July 1994 to December 2012. We selected 34,800 control-subjects by risk-set sampling. Controls were individually matched for age, sex, municipality and time. Person data on use of PPI and other drugs and hospitalization diagnoses in a 5-year period were extracted from nationwide health registries. A comorbidity index (CMI) was constructed. We calculated the association with use of PPIs and related drugs within 30 days (current use) and other time windows before the index date. Using conditional logistic regression, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.RESULTS: The adjusted OR with current use of PPIs for development of listeriosis was 2.81 (95% confidence interval [CI], 2.14-3.69). PPI usage up to 90 days before the index date remained statistically significant. Subgroup analyses revealed increasing ORs with decreasing age and level of comorbidity, and an increased OR for concurrent glucocorticoid treatment (OR 4.61; 95% CI, 3.01-7.06). No significant association was found for current use of histamine-2-receptor antagonists, adjusted OR, 1.82 (95% CI, 0.89-3.71).CONCLUSIONS: Prescribed PPIs were associated with an increased risk of listeriosis. The risk waned with time since last prescription redemption. PPIs may have unwanted side effects in vulnerable populations groups.

AB - BACKGROUND: Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis. We aimed to investigate a potential association in cases of non-pregnancy associated listeriosis, using registry data.METHODS: We conducted a population-based case-control study using Danish health registries. Case-patients (n=721) were defined as patients ≥45 years notified with listeriosis, July 1994 to December 2012. We selected 34,800 control-subjects by risk-set sampling. Controls were individually matched for age, sex, municipality and time. Person data on use of PPI and other drugs and hospitalization diagnoses in a 5-year period were extracted from nationwide health registries. A comorbidity index (CMI) was constructed. We calculated the association with use of PPIs and related drugs within 30 days (current use) and other time windows before the index date. Using conditional logistic regression, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.RESULTS: The adjusted OR with current use of PPIs for development of listeriosis was 2.81 (95% confidence interval [CI], 2.14-3.69). PPI usage up to 90 days before the index date remained statistically significant. Subgroup analyses revealed increasing ORs with decreasing age and level of comorbidity, and an increased OR for concurrent glucocorticoid treatment (OR 4.61; 95% CI, 3.01-7.06). No significant association was found for current use of histamine-2-receptor antagonists, adjusted OR, 1.82 (95% CI, 0.89-3.71).CONCLUSIONS: Prescribed PPIs were associated with an increased risk of listeriosis. The risk waned with time since last prescription redemption. PPIs may have unwanted side effects in vulnerable populations groups.

KW - Journal Article

U2 - 10.1093/cid/ciw860

DO - 10.1093/cid/ciw860

M3 - Journal article

C2 - 28013257

VL - 64

SP - 845

EP - 851

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -